Your browser is no longer supported. Please, upgrade your browser.
Settings
ALNY Alnylam Pharmaceuticals, Inc. daily Stock Chart
ALNY [NASD]
Alnylam Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-7.83 Insider Own0.30% Shs Outstand115.99M Perf Week7.52%
Market Cap14.85B Forward P/E- EPS next Y-5.61 Insider Trans-44.81% Shs Float115.24M Perf Month7.56%
Income-890.90M PEG- EPS next Q-1.73 Inst Own94.60% Short Float3.23% Perf Quarter1.43%
Sales401.00M P/S37.02 EPS this Y-7.00% Inst Trans-2.90% Short Ratio7.09 Perf Half Y-3.63%
Book/sh10.48 P/B12.62 EPS next Y21.10% ROA-31.40% Target Price163.61 Perf Year11.54%
Cash/sh16.34 P/C8.10 EPS next 5Y46.09% ROE-66.00% 52W Range84.97 - 167.33 Perf YTD14.85%
Dividend- P/FCF- EPS past 5Y-10.80% ROI-65.40% 52W High-22.48% Beta1.45
Dividend %- Quick Ratio5.20 Sales past 5Y34.20% Gross Margin83.20% 52W Low52.67% ATR5.09
Employees1323 Current Ratio5.30 Sales Q/Q79.60% Oper. Margin- RSI (14)49.23 Volatility3.32% 4.22%
OptionableYes Debt/Eq0.00 EPS Q/Q-13.80% Profit Margin- Rel Volume0.37 Prev Close132.27
ShortableYes LT Debt/Eq0.00 EarningsNov 05 BMO Payout- Avg Volume525.37K Price129.72
Recom2.00 SMA200.28% SMA50-3.54% SMA200-2.67% Volume96,916 Change-1.93%
Sep-30-20Resumed Berenberg Hold $145
Sep-08-20Initiated Citigroup Buy $170
Aug-11-20Downgrade Oppenheimer Outperform → Perform
May-13-20Initiated RBC Capital Mkts Sector Perform $150
May-07-20Downgrade JP Morgan Overweight → Neutral $133 → $137
Apr-24-20Resumed Evercore ISI Outperform $160
Mar-19-20Initiated Berenberg Buy $200
Dec-19-19Reiterated Chardan Capital Markets Buy $150 → $190
Nov-20-19Initiated Oppenheimer Outperform $128
Nov-13-19Initiated BofA/Merrill Buy $110
May-23-19Resumed Goldman Neutral $80
Apr-12-19Initiated Evercore ISI Outperform
Mar-06-19Upgrade Evercore ISI In-line → Outperform
Mar-05-19Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-23-19Initiated UBS Neutral $87
Oct-01-18Initiated Cantor Fitzgerald Overweight $135
Aug-13-18Reiterated Stifel Buy $125 → $123
Aug-07-18Upgrade Stifel Hold → Buy $95 → $125
May-04-18Reiterated Stifel Hold $107 → $95
Mar-28-18Initiated Evercore ISI In-line
Nov-30-20 08:54AM  
08:24AM  
08:24AM  
Nov-25-20 01:16PM  
09:08AM  
08:00AM  
Nov-24-20 08:12AM  
07:01AM  
07:00AM  
Nov-20-20 10:08AM  
Nov-19-20 07:00AM  
Nov-13-20 09:00AM  
Nov-07-20 07:24AM  
Nov-06-20 10:48AM  
Nov-05-20 10:01PM  
08:00AM  
Nov-04-20 08:30AM  
Nov-03-20 01:14PM  
Nov-02-20 04:00PM  
Oct-31-20 08:00AM  
Oct-30-20 07:00AM  
Oct-29-20 03:06PM  
12:35PM  
Oct-22-20 04:00PM  
12:33PM  
10:00AM  
Oct-19-20 12:46PM  
09:55AM  
Oct-18-20 06:43AM  
Oct-16-20 06:00AM  
Oct-15-20 04:12PM  
Oct-11-20 08:33AM  
Oct-01-20 10:50AM  
Sep-30-20 04:19PM  
07:00AM  
Sep-28-20 04:00PM  
Sep-16-20 04:24PM  
Sep-09-20 09:47PM  
06:29AM  
Sep-05-20 11:32AM  
Sep-04-20 06:35PM  
Sep-03-20 07:30AM  
Sep-02-20 08:00AM  
Aug-27-20 10:17AM  
08:13AM  
Aug-17-20 07:30AM  
Aug-07-20 10:56AM  
Aug-06-20 11:25AM  
08:00AM  
07:30AM  
Aug-03-20 07:30AM  
Jul-30-20 12:33PM  
Jul-23-20 11:02AM  
08:00AM  
Jul-14-20 12:00PM  
Jul-13-20 10:45AM  
07:28AM  
Jul-09-20 08:54PM  
Jul-08-20 07:57AM  
Jul-01-20 11:48AM  
07:00AM  
Jun-30-20 09:00AM  
Jun-28-20 04:51PM  
Jun-18-20 07:00AM  
Jun-17-20 04:00PM  
09:50AM  
Jun-10-20 05:07PM  
Jun-08-20 10:00AM  
09:00AM  
03:24AM  
Jun-07-20 07:15AM  
Jun-05-20 11:32AM  
Jun-04-20 03:54PM  
Jun-02-20 08:00AM  
Jun-01-20 07:00AM  
May-27-20 09:47AM  
May-26-20 04:00PM  
07:00AM  
07:00AM  
May-25-20 11:30AM  
May-22-20 12:30PM  
May-21-20 07:03AM  
May-12-20 04:01PM  
May-11-20 10:46AM  
08:00AM  
May-07-20 12:00PM  
11:30AM  
10:25AM  
May-06-20 06:30PM  
01:27PM  
09:25AM  
08:00AM  
May-05-20 11:45AM  
11:40AM  
10:40AM  
May-04-20 10:23AM  
08:24AM  
07:46AM  
07:30AM  
May-03-20 08:37AM  
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHARP PHILLIP ADirectorNov 25Option Exercise9.3030,000279,000265,633Nov 30 04:03 PM
SHARP PHILLIP ADirectorNov 25Sale124.8930,0003,746,749235,633Nov 30 04:03 PM
MARAGANORE JOHNChief Executive OfficerNov 19Option Exercise9.1434,765317,752232,354Nov 20 04:02 PM
MARAGANORE JOHNChief Executive OfficerNov 19Sale124.2334,7654,319,025197,589Nov 20 04:02 PM
Vaishnaw AkshayPresident, R&DSep 29Option Exercise42.2297140,99615,090Oct 01 04:03 PM
Vaishnaw AkshayPresident, R&DSep 29Sale140.00971135,94014,119Oct 01 04:03 PM
Greene Barry EPresidentSep 09Option Exercise9.1444,530407,004114,873Sep 11 05:11 PM
Greene Barry EPresidentSep 09Sale123.2344,5305,487,59470,343Sep 11 05:11 PM
MARAGANORE JOHNChief Executive OfficerAug 20Option Exercise9.1434,765317,752232,354Aug 21 04:06 PM
MARAGANORE JOHNChief Executive OfficerAug 20Sale136.1334,7654,732,542197,589Aug 21 04:06 PM
Greene Barry EPresidentAug 10Option Exercise70.954,931349,87167,167Aug 11 04:09 PM
KEATING LAURIEEVP, Chief Legal OfficerJul 13Option Exercise87.1635,7503,116,06650,242Jul 14 04:03 PM
KEATING LAURIEEVP, Chief Legal OfficerJul 13Sale160.6747,2507,591,7902,992Jul 14 04:03 PM
Greenstreet YvonneChief Operating OfficerJul 10Option Exercise77.1046,6393,595,86751,459Jul 14 04:02 PM
Greenstreet YvonneChief Operating OfficerJul 10Sale161.0046,6397,508,8794,820Jul 14 04:02 PM
Greenstreet YvonneChief Operating OfficerJul 09Option Exercise43.1411,236484,74316,056Jul 10 04:03 PM
Greenstreet YvonneChief Operating OfficerJul 09Sale161.0011,2361,808,9964,820Jul 10 04:03 PM
Greene Barry EPresidentJul 07Option Exercise9.1422,265203,50284,501Jul 09 04:02 PM
Greene Barry EPresidentJul 07Sale159.9922,2653,562,17762,236Jul 09 04:02 PM
Vaishnaw AkshayPresident, R&DJun 22Option Exercise42.2297040,95315,089Jun 24 04:02 PM
Vaishnaw AkshayPresident, R&DJun 22Sale151.07970146,53614,119Jun 24 04:02 PM
MARAGANORE JOHNChief Executive OfficerMay 20Option Exercise9.1434,765317,752232,354May 22 04:03 PM
MARAGANORE JOHNChief Executive OfficerMay 20Sale143.2234,7654,978,983197,589May 22 04:03 PM
Greenstreet YvonneChief Operating OfficerMay 06Option Exercise77.1050,0003,855,00054,820May 07 04:08 PM
Greene Barry EPresidentMay 06Option Exercise9.1422,265203,50284,501May 07 04:09 PM
Greene Barry EPresidentMay 06Sale149.9922,2653,339,52762,236May 07 04:09 PM
Greenstreet YvonneChief Operating OfficerMay 06Sale150.0050,0007,500,0004,820May 07 04:08 PM
Greenstreet YvonneChief Operating OfficerMay 05Option Exercise42.227,811329,78012,631May 07 04:08 PM
Greenstreet YvonneChief Operating OfficerMay 05Sale140.007,8111,093,5404,820May 07 04:08 PM
KEATING LAURIEEVP, Chief Legal OfficerApr 20Option Exercise77.4010,000774,00024,492Apr 22 04:07 PM
Vaishnaw AkshayPresident, R&DApr 20Option Exercise42.2221,971927,61636,090Apr 22 04:06 PM
Vaishnaw AkshayPresident, R&DApr 20Sale140.0021,9713,075,94014,119Apr 22 04:06 PM
KEATING LAURIEEVP, Chief Legal OfficerApr 20Sale139.0010,0001,390,00014,492Apr 22 04:07 PM
MARAGANORE JOHNChief Executive OfficerFeb 20Option Exercise9.1434,765317,752224,758Feb 21 04:02 PM
MARAGANORE JOHNChief Executive OfficerFeb 20Sale131.8534,7654,583,674189,993Feb 21 04:02 PM
SHARP PHILLIP ADirectorFeb 12Option Exercise12.4830,000374,400265,633Feb 13 04:06 PM
SHARP PHILLIP ADirectorFeb 12Sale130.0030,0003,900,000235,633Feb 13 04:06 PM
Greenstreet YvonneChief Operating OfficerFeb 10Option Exercise42.225,600236,43211,808Feb 11 04:08 PM
PAUL STEVEN MDirectorFeb 10Option Exercise14.6730,000440,10031,000Feb 11 04:08 PM
KEATING LAURIEEVP, Chief Legal OfficerFeb 10Option Exercise77.4010,000774,00022,258Feb 12 04:03 PM
KEATING LAURIEEVP, Chief Legal OfficerFeb 10Sale129.0010,0001,290,00012,258Feb 12 04:03 PM
Greenstreet YvonneChief Operating OfficerFeb 10Sale130.009,8921,285,9601,916Feb 11 04:08 PM
PAUL STEVEN MDirectorFeb 10Sale130.0030,0003,900,0001,000Feb 11 04:08 PM
Vaishnaw AkshayPresident, R&DFeb 07Option Exercise42.2222,750960,50534,923Feb 11 04:08 PM
Greenstreet YvonneChief Operating OfficerFeb 07Option Exercise42.226,250263,87512,458Feb 11 04:08 PM
Greenstreet YvonneChief Operating OfficerFeb 07Sale123.906,250774,3756,208Feb 11 04:08 PM
Vaishnaw AkshayPresident, R&DFeb 07Sale125.0023,7082,963,50011,215Feb 11 04:08 PM
KEATING LAURIEEVP, Chief Legal OfficerJan 29Option Exercise77.406,337490,48414,932Jan 31 04:05 PM
KEATING LAURIEEVP, Chief Legal OfficerJan 29Sale119.006,337754,1038,595Jan 31 04:05 PM
KEATING LAURIEEVP, Chief Legal OfficerJan 27Option Exercise42.2234,3741,451,27049,632Jan 29 04:03 PM
KEATING LAURIEEVP, Chief Legal OfficerJan 27Sale117.7041,0374,829,9708,595Jan 29 04:03 PM